Lates News

According to a news bulletin from Every AI, Donghai Securities released a research report on September 1, giving Hai'er Biology (688139.SH) a buy rating. The reasons for the rating mainly include: 1) short-term performance pressure, outstanding performance in overseas markets; 2) gradual recovery in low-temperature storage business, multi-category share breakthrough in laboratory solutions; 3) medical innovation sector: strong growth momentum in new industries, smart medication and blood technology advancing side by side. (Everyday Economic News)